Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis

References

• de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743–752. doi:10.1016/j.jhep.2015.05.022.
   PubMed Web of Science ®Google Scholar
• Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, et al. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr 2017;129:135–158. doi:10.1007/s00508-017-1262-3.
   PubMed Web of Science ®Google Scholar
• Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol 2007;46:727–733. doi:10.1016/j.jhep.2007.01.015.
   PubMed Web of Science ®Google Scholar
• Tripodi A. Hemostasis in acute and chronic liver disease. Semin Liver Dis 2017;37:28–32. doi:10.1055/s-0036-1597770.
   PubMed Web of Science ®Google Scholar
• Intagliata NM, Argo CK, Stine JG, Lisman T, Caldwell SH, Violi F. Concepts and controversies in haemostasis and thrombosis associated with liver disease. Proceedings of the 7th international coagulation in liver disease conference. Thromb Haemost 2018;118:1491–1506. doi:10.1055/s-0038-1666861.
   PubMed Web of Science ®Google Scholar
• Zermatten MG, Fraga M, Moradpour D, Bertaggia Calderara D, Aliotta A, Stirnimann G, De Gottardi A, Alberio L, et al. Haemostatic alterations in cirrhotic patients: from primary haemostasis to fibrinolysis. Hepatology 2020;2135–2148. doi:10.1002/hep.31201.
   PubMedGoogle Scholar
• Lisman T, Kwaan HC. Hemostatic dysfunction in liver diseases. Semin Thromb Hemost 2015;41:445–446. doi:10.1055/s-0035-1550441.
   PubMed Web of Science ®Google Scholar
• Vinholt PJ, Hvas AM, Nielsen C, Söderström AC, Sprogøe U, Fialla AD, Nybo M, et al. Reduced platelet activation and platelet aggregation in patients with alcoholic liver cirrhosis. Platelets 2018;29:520–527. doi:10.1080/09537104.2017.1349308.
   PubMed Web of Science ®Google Scholar
• Alkozai EM, Porte RJ, Adelmeijer J, Zanetto A, Simioni P, Senzolo M, Lisman T, et al. No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma. Thromb Res 2015;135:292–297. doi:10.1016/j.thromres.2014.11.016.
   PubMed Web of Science ®Google Scholar
• Caldwell S, Lisman T. The cirrhotic platelet: shedding light on an enigma. Hepatology 2017;65:407–410. doi:10.1002/hep.28931.
   PubMed Web of Science ®Google Scholar
• Ogasawara F, Fusegawa H, Haruki Y, Shiraishi K, Watanabe N, Matsuzaki S, et al. Platelet activation in patients with alcoholic liver disease. Tokai J Exp Clin Med 2005;30:41–48.
   PubMedGoogle Scholar
• Lisman T, Bongers TN, Adelmeijer J, Janssen HLA, de Maat MPM, de Groot PG, Leebeek FWG, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006;44:53–61. doi:10.1002/hep.21231.
   PubMed Web of Science ®Google Scholar
• Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, Ay C, Quehenberger P, Fritzer-Szekeres M, Peck-Radosavljevic M, et al. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Aliment Pharmacol Ther 2018;47:980–988. doi:10.1111/apt.14522.
   PubMed Web of Science ®Google Scholar
• Laffi G, Cominelli F, Ruggiero M, Fedi S, Chiarugi VP, La Villa G, Pinzani M, Gentilini P, et al. Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology 1988;8:1620–1626. doi:10.1002/hep.1840080625.
   PubMed Web of Science ®Google Scholar
• Ordinas A, Escolar G, Cirera I, Vinas M, Cobo F, Bosch J, Teres J, Rodés J, et al. Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. Hepatology 1996;24:1137–1142. doi:10.1002/hep.510240526.
   PubMed Web of Science ®Google Scholar
• Smolensky Koganov E, Carmichael SL, Forde EE, et al. Platelet function in thrombocytopenic patients with chronic liver disease. Blood 2017;130: 2314-2314.
   Web of Science ®Google Scholar
• Welch EL, Crooks MG, Hart SP. Agreement between blood draw techniques for assessing platelet activation by flow cytometry. Platelets 2019;30:530–534. doi:10.1080/09537104.2018.1535705.
   PubMed Web of Science ®Google Scholar
• Pedersen OH, Nissen PH, Hvas A-M. Platelet function investigation by flow cytometry: sample volume, needle size, and reference intervals. Platelets 2018;29:199–202. doi:10.1080/09537104.2017.1353684.
   PubMed Web of Science ®Google Scholar
• Blair TA, Frelinger AL, Michelson AD. 35 - flow cytometry. In: Michelson AD, editor. Platelets. 4th ed. London, United Kingdom: Academic Press, an imprint of Elsevier; 2019. p. 627–651. doi:10.1016/B978-0-12-813456-6.00035-7.
   Google Scholar
• Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int 2017;37:778–793. doi:10.1111/liv.13317.
   PubMed Web of Science ®Google Scholar
• Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B, Esteban R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008;48:1000–1007. doi:10.1016/j.jhep.2008.03.009.
   PubMed Web of Science ®Google Scholar
• Reiberger T, Schwabl P, Trauner M, Peck-Radosavljevic M, Mandorfer M, et al. Measurement of the hepatic venous pressure gradient and transjugular liver biopsy. J Vis Exp 2020. doi:10.3791/58819.
   PubMed Web of Science ®Google Scholar
• García-Pagán JC, Saffo S, Mandorfer M, Garcia-Tsao G. Where does TIPS fit in the management of patients with cirrhosis? JHEP Rep 2020;2:100122. doi:10.1016/j.jhepr.2020.100122.
   PubMedGoogle Scholar
• Queck A, Carnevale R, Uschner FE, Schierwagen R, Klein S, Jansen C, Meyer C, Praktiknjo M, Thomas D, Strassburg C, et al. Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. Gut 2020;69:1535–1536. doi:10.1136/gutjnl-2019-319044.
   PubMed Web of Science ®Google Scholar
• Grant MS. The effect of blood drawing techniques and equipment on the hemolysis of ED laboratory blood samples. J Emergency Nurs 2003;29:116–121. doi:10.1067/men.2003.66.
   PubMedGoogle Scholar
• Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, Machin S, et al. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011;155:30–44. doi:10.1111/j.1365-2141.2011.08793.x.
   PubMed Web of Science ®Google Scholar
• Mant MJ, Kappagoda CT, Taylor RF, E.Quinlan J. Platelet activation caused by cardiac catheter blood collection, and its prevention. Thromb Res 1984;33:177–187. doi:10.1016/0049-3848(84)90178-6.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Xhelili E, Steiner S, Koppensteiner R, Kopp CW, Panzer S. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: differences between peripheral and coronary angioplasty. Atherosclerosis 2014;232:119–124. doi:10.1016/j.atherosclerosis.2013.10.027.
   PubMed Web of Science ®Google Scholar
• Wadowski PP, Weikert C, Pultar J, Lee S, Eichelberger B, Koppensteiner R, Lang IM, Panzer S, Gremmel T. Ticagrelor inhibits toll-like and protease-activated receptor mediated platelet activation in acute coronary syndromes. Cardiovasc Drugs Ther 2020;34:53–63. doi:10.1007/s10557-019-06932-7.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Durstberger M, Eichelberger B, Koppensteiner R, Kopp CW, Panzer S. Human neutrophil α-defensins are associated with adenosine diphosphate-inducible neutrophil-platelet aggregate formation and response to clopidogrel in patients with atherosclerosis. Transl Res 2014;164:202–208. doi:10.1016/j.trsl.2014.03.006.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Kopp CW, Seidinger D, Giurgea G-A, Koppensteiner R, Steiner S, Panzer S. The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists’-inducible platelet reactivity. Atherosclerosis 2009;207:608–613. doi:10.1016/j.atherosclerosis.2009.05.037.
   PubMed Web of Science ®Google Scholar
• Michelson AD. Evaluation of platelet function by flow cytometry. Pathophysiol Haemost Thromb 2006;35:67–82. doi:10.1159/000093547.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. Transl Res 2013;161:421–429. doi:10.1016/j.trsl.2012.12.015.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Kopp CW, Seidinger D, Koppensteiner R, Panzer S, Sunder-Plassmann R, Mannhalter C, Steiner S. Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests. Int J Cardiol 2013;166:126–131. doi:10.1016/j.ijcard.2011.10.010.
   PubMed Web of Science ®Google Scholar
• Rubens FD, Labow RS, Waghray G, Robblee J. The importance of sampling site in the measurement of whole-blood platelet flow cytometry. J Cardiothorac Vasc Anesth 1998;12:309–313. doi:10.1016/S1053-0770(98)90012-X.
   PubMed Web of Science ®Google Scholar
• Huskens D, Sang Y, Konings J, van der Vorm L, de Laat B, Kelchtermans H, Roest M. Standardization and reference ranges for whole blood platelet function measurements using a flow cytometric platelet activation test. PLoS One 2018;13:e0192079. doi:10.1371/journal.pone.0192079.
   PubMed Web of Science ®Google Scholar
• Scheinichen D, Kleine HD, Koksch M, Brandl M, Heine J, Elsnar H-A, Bornscheuer A. Comparison of four blood sampling sites for flow-cytometric analysis of platelet function. Transfus Med Hemother 2003;30:109–114. doi:10.1159/000071723.
   Web of Science ®Google Scholar
• Schmitz G, Rothe G, Ruf A, Barlage S, Tschöpe D, Clemetson KJ, Goodall AH, Michelson AD, Nurden AT, Shankey VT, et al. European working group on clinical cell analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998;79:885–896. doi:10.1055/s-0037-1615088.
   PubMed Web of Science ®Google Scholar
• Lancé MD, Henskens YM, Nelemans P, Theunissen MHS, Oerle RV, Spronk HM, Marcus MAE. Do blood collection methods influence whole-blood platelet function analysis? Platelets 2013;24:275–281. doi:10.3109/09537104.2012.689038.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Frelinger AL 3rd, Michelson AD. Platelet physiology. Semin Thromb Hemost 2016;42:191–204. doi:10.1055/s-0035-1564835.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Koppensteiner R, Kaider A, Eichelberger B, Mannhalter C, Panzer S. Impact of variables of the P-selectin - P-selectin glycoprotein ligand-1 axis on leukocyte-platelet interactions in cardiovascular disease. Thromb Haemost 2015;113:806–812. doi:10.1160/TH14-08-0690.
   PubMed Web of Science ®Google Scholar
• Plow EF, Byzova T. The biology of glycoprotein IIb-IIIa. Coron Artery Dis 1999;10:547–551. doi:10.1097/00019501-199912000-00002.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. Thromb Haemost 2014;111:474–482. doi:10.1160/TH13-07-0558.
   PubMed Web of Science ®Google Scholar
• Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL, Goldberg RJ, Michelson AD. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001;38:1002–1006.
   PubMed Web of Science ®Google Scholar
• Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104:1533–1537. doi:10.1161/hc3801.095588.
   PubMed Web of Science ®Google Scholar
• Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999;6:342–348. doi:10.1097/00062752-199909000-00012.
   PubMedGoogle Scholar
• Clemetson KJ, Clemetson JM. 9 - platelet receptors. In: Michelson AD, editor. Platelets. 4th ed. London, United Kingdom: Academic Press, an imprint of Elsevier; 2019. p. 169–192. doi:10.1016/B978-0-12-813456-6.00009-6.
   Google Scholar
• Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AO. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404–1413. doi:10.1056/NEJMoa1200933.
   PubMed Web of Science ®Google Scholar
• Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366:20–33. doi:10.1056/NEJMoa1109719.
   PubMed Web of Science ®Google Scholar